For the Leaders
Article
From Lab Bench to LinkedIn: Why Modern Scientists Need Personal Branding and Communication Skills
Personal branding and communication skills now drive funding, hiring and career growth for scientists in pharm...
De-Risking AI Biotech: How Institutional Investors Value Tech-Bio Platforms
Vaibhavi M. | Jun 27, 2026
Market Map: The Venture Capital Firms Dominating AI Drug Discovery Investments
Mrudula Kulkarni | Jun 27, 2026
Big Pharma’s Appetite For AI: Analyzing Recent M&A Deals In Small Molecule Chemistry
Simantini Singh Deo | Jun 25, 2026
Other latest content for leaders you may like to read
From Lab Bench to LinkedIn: Why Modern Scientists Need Personal Branding and Communication Skills
Personal branding and communication skills now drive funding, hiring and career growth for scientists in pharma and biotech.
by Vaibhavi M.
De-Risking AI Biotech: How Institutional Investors Value Tech-Bio Platforms
AI biotech platforms can't be valued like traditional pipelines. Here's the checklist, metrics, and methods institutional investors use to price them.
by Vaibhavi M.
Market Map: The Venture Capital Firms Dominating AI Drug Discovery Investments
ARCH, Foresite, Sequoia and a16z lead the venture capital race in AI drug discovery, see the market map and the biggest bets.
by Mrudula Kulkarni
Big Pharma’s Appetite For AI: Analyzing Recent M&A Deals In Small Molecule Chemistry
AI in drug discovery is reshaping small molecule chemistry through M&A Recursion, Exscientia, Schrödinger and Insilico lead the wave.
by Simantini Singh Deo
High-Value Partnerships: Notable AI Drug Discovery Out-Licensing Deals In Oncology
AI biotechs are out-licensing oncology assets to big pharma at scale. Here's how the deals work, who's leading, and why it's working.
by Simantini Singh Deo
